Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial
Nom du journal : Lancet Respir Med
Année : 2018
Volume : 6
Page de départ : 431
Page de fin : 441